Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.

Also called NCT04625946

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 117 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04625946
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04625946. Randomized; no masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2025-07-01 (actual). Results posted on 2026-10-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
Intervention (Drug)
Metformin
Intervention (Behavioral)
Recommendations for lifestyle modification.
Intervention (Device)
AliveCor
Lead sponsor
University of Michigan (class: other)

Record details

Record id
cardio:ct-nct04625946
Content hash
35aeec11df6d39f0a830d0b6f5051fccb2dcb3ba594dcf494b797696d47b68f2